Critical Outcome Technologies' CEO To Co-Chair Gene Forum

Critical Outcome Technologies (TSXV:COT; OTCQB:COTQF) announced their president and CEO Alison Silva will co-chair the Global Genes RARE Partnering & Investor Forum.
As quoted in the press release:

At the Global Genes RARE Partnering & Investor Forum, Ms. Silva will also moderate a panel discussion, entitled “Innovation Company Creation Models for Rare Diseases.” The panel is comprised of company executives and investors highly regarded for their roles in the creation of innovative companies focused on the development of treatments for rare diseases. The panel will discuss the evolving landscape of rare disease drug discovery and development, with a focus on innovative investment strategies. Topics will include the successes and pitfalls of new rare disease funding models, as well as the emerging drivers and trends in a field that has received growing attention from pharmaceutical companies, venture investors, government agencies, and patient advocates.
“It is an honor to be selected as a co-chair for this meeting, and I am excited to moderate this discussion focused on novel and innovative strategies new rare disease companies can employ as well as facilitate a discussion from our panelists on their models for new company creation in this space,” said Alison Silva, President and Chief Executive Officer.

Click here to read the full press release.

Source: www.marketwired.com